Biomarin fired 225 employees as part of a major restructuring effort. Credit: SOPA Images via Getty Images.

BioMarin Pharmaceuticals plans to let 225 staff members go as it reconfigures its Roctavian (valoctocogene roxaparvovec) development programme.

The company announced the reduction in workforce in a 28 August SEC filing, stating that the downsizing will play a role in its “organisational redesign efforts”. The company plans to substantially complete the structural change by the end of this year.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The US-based company declared the layoffs soon after sharing news about several organisational shifts this month.

BioMarin appointed a new executive vice president and chief business officer and also announced a pivot in its commercial focus for its lead asset Roctavian to drive commercial operations in the US, Germany, and Italy. Regulators in the three countries have already approved and reimbursed the therapy for the treatment of severe haemophilia A.

The company had also proposed a reduction in Roctavian development and manufacturing investments. In a 5 August press release, BioMarin declared that the reduction in manufacturing programs is expected to reduce the annual direct Roctavian expenses to approximately $60m, beginning next year.

The company has also chosen to stop enrolling patients into Roctavian clinical programmes, choosing to focus its efforts on treating the currently enrolled patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roctavian is a gene therapy, which acts by stimulating the production of clotting protein Factor VIII and replacing the mutant genes. This restores the body’s factor VIII plasma concentrations to adequate levels to allow for normal clotting in patients with haemophilia A.

Roctavian is the only FDA-approved gene therapy for haemophilia A. The list price for the gene therapy stands at $2.9m, making it the sixth most expensive drug in the world, as per a GlobalData analysis. This year, the therapy amassed $800,000 in Q1 2024 sales, thanks to the treatment of the first haemophilia patient with Roctavian in Italy. In 2023, the company earned $3.5m in Roctavian sales through the dosing of three patients. GlobalData predicts that sales for the therapy could reach $451m in 2030.

GlobalData is the parent company of Pharmaceutical Technology.